Assess, in Young Children, the Efficacy in Preventing Acute Otitis Media of GSK Biologicals Undecavalent Pneumococcal-Protein D Conjugate Vaccine, When Administered as a Three Dose Primary Vaccination Course During the First Year of Life With a Booster Dose in the Second Year of Life.

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 29 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pneumococcal 11-valent vaccine conjugate (Primary) ; Hepatitis A vaccine inactivated; Hepatitis B vaccine recombinant; Pneumococcal vaccine
Indications Hepatitis A; Hepatitis B; Otitis media; Pneumococcal infections
Focus Pharmacodynamics; Registrational; Therapeutic Use
Acronyms POET
Sponsors GlaxoSmithKline

Most Recent Events

No Data Available

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight